Lenny Santoro was diagnosed with prostate cancer in 2011. Thanks to clinical trials Santoro participated in at the Duke ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

A retrospective cohort study investigated the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...

Researchers identified patients with stage I-III TNBC diagnosed between 2010 and 2021 and assessed trends in NACT use, ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Targeted therapies for HER2-negative advanced breast cancer include: PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna). These drugs stop a protein known as poly-ADP ribose ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...